BioStem Technologies, Inc. (BSEM)
USD 8.3
(1.22%)
USD 8.3
(1.22%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 14.56 Million USD | 320.04% |
| 2022 | 3.46 Million USD | 29.76% |
| 2021 | 2.67 Million USD | 0.12% |
| 2020 | 2.66 Million USD | -15.4% |
| 2019 | 3.15 Million USD | -26.65% |
| 2018 | 4.3 Million USD | 41.77% |
| 2017 | 3.03 Million USD | -47.82% |
| 2016 | 5.81 Million USD | 97.95% |
| 2015 | 2.93 Million USD | 2271.79% |
| 2014 | 123.8 Thousand USD | -32.09% |
| 2013 | 182.31 Thousand USD | -51.13% |
| 2012 | 373.04 Thousand USD | -89.26% |
| 2011 | 3.47 Million USD | 28.89% |
| 2010 | 2.69 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 90.45 Million USD | 98.05% |
| 2024 Q1 | 45.67 Million USD | 212.62% |
| 2023 Q2 | 3.3 Million USD | 6.62% |
| 2023 Q3 | 5.81 Million USD | 75.88% |
| 2023 FY | 14.61 Million USD | 321.48% |
| 2023 Q4 | 14.61 Million USD | 151.31% |
| 2023 Q1 | 3.1 Million USD | -10.56% |
| 2022 Q3 | 3.89 Million USD | -14.13% |
| 2022 FY | 3.46 Million USD | 29.76% |
| 2022 Q4 | 3.46 Million USD | -11.04% |
| 2022 Q1 | 3.97 Million USD | 48.73% |
| 2022 Q2 | 4.53 Million USD | 14.21% |
| 2021 Q3 | 2.9 Million USD | 11.11% |
| 2021 FY | 2.67 Million USD | 0.12% |
| 2021 Q4 | 2.67 Million USD | -8.05% |
| 2021 Q1 | 2.8 Million USD | 5.12% |
| 2021 Q2 | 2.61 Million USD | -6.77% |
| 2020 Q3 | 3.03 Million USD | -3.06% |
| 2020 Q1 | 3.02 Million USD | -4.24% |
| 2020 Q4 | 2.66 Million USD | -11.94% |
| 2020 FY | 2.66 Million USD | -15.4% |
| 2020 Q2 | 3.12 Million USD | 3.49% |
| 2019 FY | 3.15 Million USD | -26.65% |
| 2019 Q4 | 3.15 Million USD | 0.0% |
| 2018 Q1 | 3.03 Million USD | 27.05% |
| 2018 FY | 4.3 Million USD | 41.77% |
| 2018 Q2 | 2.78 Million USD | -8.26% |
| 2017 Q1 | 5.4 Million USD | -6.94% |
| 2017 Q3 | 2.73 Million USD | -48.22% |
| 2017 Q4 | 2.39 Million USD | -12.54% |
| 2017 FY | 3.03 Million USD | -47.82% |
| 2017 Q2 | 5.27 Million USD | -2.43% |
| 2016 Q1 | 2.49 Million USD | -15.07% |
| 2016 Q4 | 5.81 Million USD | 86.44% |
| 2016 FY | 5.81 Million USD | 97.95% |
| 2016 Q2 | 3.02 Million USD | 21.15% |
| 2016 Q3 | 3.11 Million USD | 3.19% |
| 2015 Q1 | 626.03 Thousand USD | 405.65% |
| 2015 Q2 | 773.42 Thousand USD | 23.54% |
| 2015 Q4 | 2.93 Million USD | 202.36% |
| 2015 Q3 | 971.19 Thousand USD | 25.57% |
| 2015 FY | 2.93 Million USD | 2271.79% |
| 2014 Q4 | 123.8 Thousand USD | -14.86% |
| 2014 Q1 | 153.41 Thousand USD | -15.86% |
| 2014 Q2 | 144.84 Thousand USD | -5.58% |
| 2014 Q3 | 145.42 Thousand USD | 0.4% |
| 2014 FY | 123.8 Thousand USD | -32.09% |
| 2013 Q1 | 214.17 Thousand USD | 0.0% |
| 2013 Q2 | 248.32 Thousand USD | 15.94% |
| 2013 Q3 | 323.84 Thousand USD | 30.41% |
| 2013 Q4 | 182.31 Thousand USD | -43.7% |
| 2013 FY | 182.31 Thousand USD | -51.13% |
| 2012 FY | 373.04 Thousand USD | -89.26% |
| 2011 FY | 3.47 Million USD | 28.89% |
| 2010 FY | 2.69 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -630215.628% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -643.559% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -37.96% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -2537.161% |
| Rebus Holdings, Inc. | 5000.00 USD | -291105.82% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 88.818% |
| Qrons Inc. | 420.00 USD | -3466635.952% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -1789.367% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 47.895% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -2929.878% |
| Skye Bioscience, Inc. | 11.94 Million USD | -21.941% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 62.519% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -101.673% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -18969.454% |
| SQZ Biotechnologies Company | 107.18 Million USD | 86.416% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -916.757% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -20020.626% |
| Mesoblast Limited | 667.9 Million USD | 97.82% |
| Marizyme, Inc. | 22.01 Million USD | 33.862% |
| Genus plc | 1.02 Billion USD | 98.585% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -971.908% |
| Pharming Group N.V. | 462.85 Million USD | 96.854% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -339.488% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -2817.666% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -2222.215% |
| ContraFect Corporation | 20.67 Million USD | 29.589% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -3629.908% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -3709.829% |
| IMV Inc. | 31.33 Million USD | 53.532% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -251.187% |
| MultiCell Technologies, Inc. | 126.22 USD | -11535544.906% |
| ONE Bio Corp. | 70.08 Million USD | 79.225% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -1449.48% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 88.67% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -3272.671% |
| Q BioMed Inc. | 3.51 Million USD | -314.172% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 58.611% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -5472.741% |
| Biomind Labs Inc. | 73.81 Thousand USD | -19624.314% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 96.738% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -904.96% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 51.49% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -430.172% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -2017.904% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -459.324% |
| GB Sciences, Inc. | 103.44 Thousand USD | -13975.802% |
| Alpha Cognition Inc. | 2.45 Million USD | -493.772% |
| HST Global, Inc. | 1526.00 USD | -954047.51% |
| CSL Limited | 38.02 Billion USD | 99.962% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -1373.763% |
| Halberd Corporation | 10.13 Thousand USD | -143620.176% |
| Enzolytics Inc. | 361.7 Million USD | 95.975% |
| Agentix Corp. | 261.39 Thousand USD | -5470.289% |
| Resverlogix Corp. | 8.11 Million USD | -79.424% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -675.358% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.679% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 69.477% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -2176.269% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -63814.187% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -62.7% |
| AVAX Technologies, Inc. | 7.37 Million USD | -97.37% |
| Zenith Capital Corp. | 7410.00 USD | -196395.155% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.57% |
| Ember Therapeutics, Inc. | 184.00 USD | -7913101.63% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -4424.555% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -5470.886% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -1469.063% |
| Kadimastem Ltd | 2.3 Million USD | -531.935% |
| Helix BioMedix, Inc. | 3.02 Million USD | -381.318% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 72.372% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -25402.314% |
| LadRx Corporation | 2.3 Million USD | -530.894% |
| Cell Source, Inc. | 195.17 Thousand USD | -7360.274% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -4017.531% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -4017.531% |
| NovAccess Global Inc. | 62.24 Thousand USD | -23290.777% |
| Affymax, Inc. | 7.44 Million USD | -95.624% |
| Itoco Inc. | 1.4 Million USD | -939.967% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -15121.354% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -13636.124% |
| Mobile Lads Corp. | 52.00 USD | -28000459.615% |
| CytoDyn Inc. | 11.13 Million USD | -30.75% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -10084.016% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -81333.395% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -3677.273% |
| SYBLEU INC | 330.46 Thousand USD | -4305.961% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -3456.304% |
| International Stem Cell Corporation | 5.39 Million USD | -170.135% |
| Bioxytran, Inc. | 137.63 Thousand USD | -10478.685% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 2.943% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 12.176% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -18330.748% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -1583.899% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -93.698% |
| Neutra Corp. | 2851.00 USD | -510608.208% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 55.069% |
| PureTech Health plc | 693.97 Million USD | 97.902% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -80.401% |
| IXICO plc | 15.84 Million USD | 8.102% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -75.806% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 85.908% |
| CSL Limited | 38.02 Billion USD | 99.962% |
| Cellectis S.A. | 333.99 Million USD | 95.641% |